Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (LAI-1), and chemokine beta-11 (Ck beta-11)

Abstract

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human chemokine beta-11 (Ck beta-11) polypeptide and a human leukocyte adhesion inhibitor-1 (LA11) polypeptide (previously termed chemokine α1(CKα1 or cka-1), as well as Ck beta-11 and/or LAI-1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

What is claimed is:  
     
         1 . An isolated leukocyte adhesion inhibitor-1 (LAI-1) polypeptide having an amino acid sequence selected from the group consisting of: 
 (a) Val (23)-Pro (109) of SEQ ID NO:4;    (b) Val (26)-Pro (109) of SEQ ID NO:4;    (c) Thr (29)-Pro (109) of SEQ ID NO:4;    (d) Ser (30)-Pro (109) of SEQ ID NO:4;    (e) a polypeptide having an amino acid sequence identical to that of (a) except for at least one amino acid substitution;    (f) a polypeptide having an amino acid sequence identical to that of (b) except for at least one amino acid substitution;    (g) a polypeptide having an amino acid sequence identical to that of (c) except for at least one amino acid substitution; and    (h) a polypeptide having an amino acid sequence identical to that of (d) except for at least one amino acid substitution.    
     
     
         2 . The isolated polypeptide of  claim 1 , which is produced recombinantly using a baculovirus expression system.  
     
     
         3 . A method of inhibiting angiogenesis, comprising administering to an animal an effective amount of an LAI-1 polypeptide of  claim 1 .  
     
     
         4 . A method of inhibiting adhesion of peripheral blood mononuclear cells (PBMCs) to endothelial cells comprising administering to an animal an effective amount of the polypeptide of  claim 1 .  
     
     
         5 . The method of  claim 4 , wherein said inhibition alleviates or prevents joint inflammation.  
     
     
         6 . An isolated Chemokine ,-11 polypeptide selected from the group consisting of: 
 (a) Gly (22)-Ser (98) of SEQ ID NO: 2; and      (b) a polypeptide having an amino acid sequence identical to that of (a) except for at least one amino acid substitution.    
     
     
         7 . A method for attracting T-lymphocytes comprising administering to an animal an effective amount of the polypeptide of  claim 6 .  
     
     
         8 . The isolated polypeptide of  claim 1 , wherein at position 30 of said amino acid sequence, Glu is substituted for Ser.